Chapter

Second-generation HPV prophylactic vaccines

Richard BS Roden

in Vaccines for the Prevention of Cervical Cancer

Published on behalf of Oxford University Press

ISBN: 9780199543458
Published online May 2011 | e-ISBN: 9780199607181 | DOI: http://dx.doi.org/10.1093/med/9780199543458.003.0012

Series: Oxford Oncology Library

Second-generation HPV prophylactic vaccines

Show Summary Details

Preview

• The approved HPV vaccines, Gardasil® and Cervarix®, prevent infection by a subset of oncogenic HPV types, necessitating the development of highly multivalent L1 VLP vaccines or developing L2 as a single broadly protective antigen. • Vaccine may be too expensive for use in developing countries where >80% of cervical cancer cases occur. • Potential second-generation HPV preventive vaccines nearing clinical study include the following: • L1 expressed in Salmonella typhi for low-cost manufacture and oral delivery. • L1 capsomeres purified from Escherichia coli for low-cost manufacture and greater temperature stability. • L2 protein purified from E. coli for low-cost manufacture and broad protection. • A combination of tiered pricing, local manufacture, and new technology is required to realize the full potential of HPV vaccination worldwide.

Chapter.  2837 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.